353 studies found for:    "primary myelofibrosis"
Show Display Options
RSS Create an RSS feed from your search for:
"primary myelofibrosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemic Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
2 Completed
Has Results
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Conditions: Primary Myelofibrosis (PMF);   Post Polycythaemia Myelofibrosis (PPV MF);   Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Intervention: Drug: INC424
3 Enrolling by invitation Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
4 Completed Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
5 Completed Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Momelotinib
6 Completed
Has Results
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib
7 Active, not recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
8 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
9 Active, not recruiting An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Fibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
10 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
11 Not yet recruiting Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Conditions: Primary Myelofibrosis (PMF);   Post-polycythemia Vera (Post-PV) Myelofibrosis;   Postessential Thrombocythemia (Post-ET) Myelofibrosis
Intervention: Drug: MMB
12 Withdrawn Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Conditions: Primary Myelofibrosis;   Primary Pulmonary Hypertension;   Secondary Myelofibrosis;   Pulmonary Arterial Hypertension
Intervention:
13 Terminated
Has Results
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
14 Recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
15 Available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
16 Completed Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Momelotinib
17 Recruiting A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Biological: PRM-151;   Drug: Ruxolitinib
18 Unknown  Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis
Conditions: Myelodysplastic Syndrome;   Primary Myelofibrosis
Intervention:
19 Recruiting Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Drug: Momelotinib;   Drug: Ruxolitinib;   Drug: Placebo to match momelotinib;   Drug: Placebo to match ruxolitinib
20 Active, not recruiting LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Conditions: Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-Essential Thrombocythemia Related Myelofibrosis
Intervention: Drug: LBH589

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years